• Quoin Pharmaceuticals posted a wider net loss of $5 million, versus $3.8 million a year earlier, with loss per ADS improving to $1.77 from $6.5.
• Operating expenses climbed to $5.13 million from $3.96 million, led by R&D spending of $3.43 million versus $2.37 million.
• Cash, cash equivalents and marketable securities totaled about $14 million as of March 31, with the company projecting funding into 2027.
• FDA granted Fast Track designation for QRX003 lotion (4%) in Netherton syndrome; a Type C meeting indicated a single Phase 3 study may support US marketing approval and FDA was open to a pivotal design without a traditional upfront vehicle or placebo control.
• Quoin filed for Breakthrough Medicine designation for QRX003 in Saudi Arabia, sought orphan drug designation in Japan where MHLW confirmed eligibility for orphan status and fast-track review, and reiterated Phase 3 recruitment completion by end-2026 with a potential NDA filing in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070830PRIMZONEFULLFEED9715337) on May 07, 2026, and is solely responsible for the information contained therein.